$HBAN

HUNTINGTON BANCSHARES INC /MD/ (HBAN): Results of Operations and Financial Condition

HUNTINGTON BANCSHARES INC /MD/ (HBAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 hban20260630_8kex992.htm EX-99.2 Document Exhibit 99.2 HUNTINGTON BANCSHARES INCORPORATED Quarterly Financial Supplement June 30, 2026 Table of Contents Quarterly Key Statistics 1 Year-to-Date Key Statistics 2 Consolidated Balance Sheets 4 Loans and Leases Composition 5

Original reporting
Published Jul 23, 2026, 10:16 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 10:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$HBAN
Neutral
medium confidence
Mentioned
$HBAN
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HBANNeutralMed
01

Why it matters

Updated quarterly figures for net interest income, net interest margin, credit loss provision, and nonperforming asset indicators can affect expectations for earnings power and credit costs going into the next reporting cycle.

02

Market read

Provides fresh, primary quarterly operating and credit-quality datapoints for HBAN that can be used to reframe near-term earnings and risk assumptions.

03

What to watch

Traders may need the full supplement tables (credit reserves analysis, net charge-offs, and year-to-date metrics) to judge whether changes are driven by one-offs versus trend.

Relevance 7/10Novelty 6/10Timing: as filed on SEC EDGAR, for traders updating positions ahead of subsequent earnings coverage

Background

The 8-K includes Exhibit 99.2, a quarterly financial supplement for Huntington Bancshares for the quarter ended June 30, 2026, with key statistics and balance sheet and credit metrics.

Company-level read

Ticker impact

$HBANNeutralMedium confidence
Context

Huntington Bancshares filed an 8-K with quarterly financial supplement showing 2Q26 net interest income, credit loss provision, and net income figures.

Expected impact

Likely modest, unless investors focus on a specific deterioration or improvement in credit reserves, NAL/NPA ratios, or NIM versus prior quarter.

Evidence & confidence

This is a primary-source quarterly results supplement, but the excerpt does not include management guidance or a standout single datapoint beyond the presented quarter-over-quarter changes.

Market effects

Banking sector read-through via reported NIM, credit loss provision, and nonperforming asset ratios, which influence regional bank credit and earnings models.

Limited direct regional impact beyond sentiment around US bank credit quality and margin trends.

Low, as the disclosure is company-specific and not tied to global macro shocks in the excerpt.

Counterpoint

Quarterly improvement in income metrics may be offset by underlying credit deterioration not fully captured by headline NCO/NPA ratios in the excerpt.

Key entities

  • Huntington Bancshares Incorporated

    Subject of the SEC 8-K filing with quarterly financial supplement metrics for the quarter ended June 30, 2026.

Related articles

$HBANMed

Huntington Bancshares Q2 Earnings Call Highlights

Huntington Bancshares management said it is on track for $365 million in Cadence cost synergies in Q4 and $435 million in combined Veritex and Cadence run-rate expense synergies by Q4. Q2 average loans rose $15B (8.6%) and deposits rose $18.8B (9.2%). Net interest income was $2.1B (+8.5%); value-added fees rose over 60% YoY. Outlook: NII pressured by deposit costs; EPS target for 2027 is $1.90 to $1.93.

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

$IXMed

Orix Corp Ads Q1 Earnings Call Highlights

ORIX (NYSE: IX) discussed Q1 results and outlook on an earnings call, including potential Q3 Kioxia sale and valuation losses tied to Kioxia’s end-September share price. ORIX shifted its dividend basis to adjusted profits, targeting an interim dividend of JPY 107.27 per share and full-year JPY 187.36. It reported JPY 115.7B capital gains and about JPY 300B capital-recycling inflows, and continued a JPY 250B buyback.